CHMP's recommendations include Aimovig, Orphan candidates

Among a host of positive recommendations announced Friday, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin deficiency.

The committee recommended

Read the full 361 word article

User Sign In